391 related articles for article (PubMed ID: 36929485)
1. Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.
Yu X; Hao Y; Zhu Z; Zhang W; Liu B; Ma M; Zhang X; Wei N; Wang J; Liu F
Clin Drug Investig; 2023 Apr; 43(4):241-250. PubMed ID: 36929485
[TBL] [Abstract][Full Text] [Related]
2. Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective.
Alsumali A; Djatche LM; Briggs A; Liu R; Diakite I; Patel D; Wang Y; Lautsch D
Pharmacoeconomics; 2021 Nov; 39(11):1343-1354. PubMed ID: 34623625
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System.
Wang Z; Lou Y; Wang Q; Sun M; Li X; Wang Y; Wang Y
Clin Drug Investig; 2023 Apr; 43(4):265-275. PubMed ID: 36976423
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
Chew DS; Li Y; Bigelow R; Cowper PA; Anstrom KJ; Daniels MR; Davidson-Ray L; Hernandez AF; O'Connor CM; Armstrong PW; Mark DB;
Circulation; 2023 Oct; 148(14):1087-1098. PubMed ID: 37671551
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
Liang L; Bin-Chia Wu D; Aziz MIA; Wong R; Sim D; Leong KTG; Wei YQ; Tan D; Ng K
J Med Econ; 2018 Feb; 21(2):174-181. PubMed ID: 28959905
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
Krittayaphong R; Permsuwan U
Am J Cardiovasc Drugs; 2022 Sep; 22(5):577-590. PubMed ID: 35796952
[TBL] [Abstract][Full Text] [Related]
7. Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event.
Alsumali A; Lautsch D; Liu R; Patel D; Nanji S; Djatche LM
Adv Ther; 2021 May; 38(5):2631-2643. PubMed ID: 33860924
[TBL] [Abstract][Full Text] [Related]
8. Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40.
Kolovos S; Bellanca L; Groyer H; Rosano GMC; Solé A; Gaultney J; Linden S
ESC Heart Fail; 2023 Dec; 10(6):3385-3397. PubMed ID: 37670496
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Idehara K; Nitta D
ESC Heart Fail; 2024 Feb; 11(1):261-270. PubMed ID: 37969049
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
Isaza N; Calvachi P; Raber I; Liu CL; Bellows BK; Hernandez I; Shen C; Gavin MC; Garan AR; Kazi DS
JAMA Netw Open; 2021 Jul; 4(7):e2114501. PubMed ID: 34313742
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
Tang Y; Sang H
Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229
[No Abstract] [Full Text] [Related]
12. Sacubitril-valsartan
Hu T; Liu Y; Lou Y
Front Pharmacol; 2023; 14():925375. PubMed ID: 36937882
[No Abstract] [Full Text] [Related]
13. Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China.
Lou Y; Hu T; Huang J
Am J Cardiovasc Drugs; 2023 Jan; 23(1):47-57. PubMed ID: 36207658
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction.
Krittayaphong R; Permsuwan U
Int J Cardiol; 2021 Jan; 322():183-190. PubMed ID: 32800910
[TBL] [Abstract][Full Text] [Related]
16. A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.
Tafazzoli A; Reifsnider OS; Bellanca L; Ishak J; Carrasco M; Rakonczai P; Stargardter M; Linden S
Eur J Health Econ; 2023 Dec; 24(9):1441-1454. PubMed ID: 36463524
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
McEwan P; Darlington O; McMurray JJV; Jhund PS; Docherty KF; Böhm M; Petrie MC; Bergenheim K; Qin L
Eur J Heart Fail; 2020 Nov; 22(11):2147-2156. PubMed ID: 32749733
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction.
Krittayaphong R; Yadee J; Permsuwan U
Clinicoecon Outcomes Res; 2019; 11():767-777. PubMed ID: 31824183
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure).
Sanders-van Wijk S; van Asselt AD; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Vuillomenet A; Peter M; Pfisterer ME; Brunner-La Rocca HP;
JACC Heart Fail; 2013 Feb; 1(1):64-71. PubMed ID: 24621800
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
Zhou J; Liew D; Kaye DM; Zoungas S; Stub D
Circ Cardiovasc Qual Outcomes; 2022 Oct; 15(10):e008638. PubMed ID: 36252135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
